BioSpace News Archive

NRGene, an AI based genomic company operating in the agricultural and livestock industry, announced that it has successfully completed its initial public offering on the Tel Aviv Stock Exchange.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that Ton Schumacher, Ph.D., Principal Investigator at the Netherlands Cancer Institute and chair of Allogene’s Scientific Advisory Board, has been awarded the 2021 Jeantet-Collen Prize for Translational Medicine.

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it has entered into a clinical collaboration with Nelum Corp. to evaluate the safety and efficacy of zalifrelimab,

BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. (“Eidos”) (formerly Nasdaq: EIDX) common stock that BridgeBio did not already own.

GeneDx, Inc., a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today launched several new genetic tests, including repeat expansion analysis for spinocerebellar ataxia (SCA), Friedreich ataxia, and other common forms of hereditary ataxias.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 25 , at 4:30 p.m. ET to discuss fourth quarter and full year 2020 financial results and provide a general business update.

OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, announced today that its ORP-101 molecule successfully cleared its first interim futility analysis in a Phase 2 clinical trial for treatment of irritable bowel syndrome with diarrhea (IBS-D).

Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations

Simulations Plus, Inc., a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, announced that it has entered into a distribution agreement with the Institute of Pharmaceutical Sciences to provide marketing, sales, and technical support to organizations within South America.

AmerisourceBergen, a global healthcare solutions leader, unveiled today a new company brand, including a new logo, website and renewed design, all of which reflect the differentiated and innovative value the company brings to its customers, associates and global healthcare marketplace.